Bioqube Ventures’ Post

One of the greatest things about being an individual biotech investor is that you don't have to have insider access or special friends at Venture Capital funds In order to invest in embryonic, very early stage biotech firms. In today's public market, there are many fledgling biotech companies that are years away from having a viable product. There's even a few public companies that don't even have viable products in clinical testing yet. Just a few collection of good molecules and hopeful prayers. If you have a taste for risk and you want to get in on the latest innovations before they're even profitable, check out names that make up the exchange traded fund XBI. You'll save a bundle on fees, enjoy more liquidity and more transparency than investing in a VC fund but the effect will basically be the same. These are very young companies. #Biotech #Biotechnology #Wallstreet

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

🤑 🤑 🤑 $17B+ raised in new VC biopharma funds so far in 2024, according to the latest Stephen Hansen analysis in BioCentury Inc. 🤑 🤑 🤑 Since the article’s publication this afternoon, I’ve already received 4 calls — 2 from VCs and 2 from private biopharmas — requesting access to underlying data and insights into how these funds are being deployed. BONUS: Our BioCentury BCIQ database provides the underlying data enabling you to run your own queries with your set of assumptions. Key takeaways from the article: 💹 $3.6B raised by Flagship Pioneering: The largest fund close of 2024, including $2.6B for Fund VIII and $1B for side funds. 💹 $3B raised by Arch Venture Partners: Another major player, focusing on early-stage innovation. 💹 €2.1B raised by Forbion: Includes €1.2B for Forbion Growth Opportunities Fund III, the largest European biopharma fund ever. 💹 Focus on AI/ML and digital health: Nine of the funds are geared toward advancing AI and digital health technologies. 💹 Late-stage & growth equity: Fourteen of the funds have a mandate for late-stage or growth equity investments, highlighting a broader shift in capital deployment. #VentureCapital #Biopharma #Investment #Biotech #AI Link to article and analysis in COMMENTS 👇👇👇

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

Loop Biotech has found its match for you to join us as a shareholder! 🚀 Say hello to Invesdor Benelux – our chosen investor platform. Why did we choose Invesdor (formerly OnePlanetCrowd)? 🏆 Largest impacting investing platform in Europe with over 180K loyal members. 🇪🇺With Invesdor everyone in Europe is able to invest in Loop Biotech. ✅ It is a user-friendly platform that is simple and safe. 🌱 Just like our mission, their community has a big focus on sustainability. This is your final reminder to pre-register before the deadline (23:59 March 12). Click on the link in the comments and register now! ☠️ Keep you posted! 👀 #investment #invesdor #greentech #loopbiotech #gogreen Invesdor Nordics Invesdor DACH Let’s go: Maarten de Jong, Peter Vriesman, Marianne Bakker, Jan-Eric Müller 💥

So far in 2024, at least 25 VCs have collectively raised $17.3 bn to fuel the biopharma industry! Highlights include: 🧬 Flagship Pioneering leading with $3.6 bn 🧪 Arch Venture Partners securing $3 bn for Fund XIII. 💊 Forbion’s €2.1 bn ($2.3 bn) close, including a record-setting €1.2 bn for their late-stage fund, making it the largest-ever European biopharma fund. This influx of capital is a significant boost for AI/ML, digital health, and late-stage growth equity investments. 🚀 For more details, check out the BioCentury Inc. article by Stephen Hansen & Matthew Krebs. 🌐 #Biotech #VentureCapital #Biopharma #Investment #DigitalHealth #Growth

🚀 NLC is making headlines as the Financial Times features Peter Veldman, senior advisor to EQT (Europe's largest Private Equity firm) and NLC Health Ventures, discussing the venture building model and its increasing recognition as an emerging asset class. Want to learn more? Send a DM! #NLC #privateequity #venturebuilding #assetclass #healthtech #biotech #financialtimes

Forbion Raises Over €2 Billion Across Two New Funds, Bringing Total Assets Under Management to €5 Billion   We are thrilled to announce our largest fundraising to date, securing over €2 billion ($2.2 billion) for two new funds. Forbion Growth Opportunities Fund III closed at €1.2 billion ($1.3 billion), and Forbion Ventures Fund VII raised €890 million ($980 million), bringing our total assets under management to €5 billion ($5.5 billion). This significant fundraising follows a period of outstanding performance, with six recent exits valued at over $1 billion each. Forbion’s continued growth reflects our commitment to supporting and building life sciences companies that drive impactful change across the healthcare landscape. We look forward to leveraging this new capital to continue our mission of impacting the future of medicine. We are grateful for the trust and support from our investors as we work to accelerate innovation in the life sciences sector. Click on the following link to learn more: https://lnkd.in/eUrYVC2k #Forbion #LifeSciences #VentureCapital #Fundraising #HealthcareInnovation #Biotech #GrowthOpportunities #InvestingInInnovation 

🌟 Big Moves in Biotech: Basking Biosciences Inc Secures $55M in Financing! 🌟 In an impressive stride for the biotech industry, Basking has announced the successful closure of a significant $55 million financing round. This round marks a pivotal moment for the company, known for its innovative work in stroke treatment and drug development. Leading the charge was ARCH Venture Partners, accompanied by a roster of new investors including Insight Partners, Platanus,Solas BioVentures, and RTW Investments, LP. The financing round also saw continued support from existing backers such as Longview Ventures, Rev1 Ventures, and The Ohio State University. This financial infusion is set to catalyze Basking's ambitious plans to revolutionize the acute ischemic stroke (AIS) field, alongside its broader goals in drug development and clinical research. The company's focus on accelerating the development of groundbreaking treatments promises to bring new hope to patients and families affected by stroke, showcasing the potential of cutting-edge science to make a real-world impact. The success of this financing round underscores the confidence of the investment community in Basking's vision and its commitment to addressing some of the most challenging issues in healthcare today. It also highlights the vital role of collaborative efforts in advancing medical research and innovation, with both new and existing partners rallying behind Basking's mission. As Basking moves forward with its enhanced capabilities and resources, the biotech community watches with anticipation. The company's progress is a beacon of what's possible when innovative minds, significant investment, and a shared commitment to improving patient outcomes converge. Congratulations to the Basking team, their investors, and advisors on this remarkable achievement. The journey ahead promises exciting developments in AIS treatment and beyond, signaling a new era of possibilities in healthcare and biotechnology. #Biotech #Financing #Innovation #DrugDevelopment #ClinicalResearch #StrokeTreatment

Which one to choose? European #medtech and #biotech companies might find engaging in a #reversemerger (RM) with a US-based #Nasdaq-listed company to be an appealing alternative to a straight #IPO. Undoubtedly, access to the liquid US capital market and a larger #investor base can facilitate funding of a growing business and frequently is seen as attractive exit option for investors. However, CEOs and board members are faced with the challenge to select the right procedure: standard RM or RM under the ‘sign-and-close’ mechanism – which one to choose? Thomas Meier, Dr. from Viopas Venture Consulting GmbH provides interesting answers to this question in his article on Plattform Life Sciences. The link to the article can be found in the comments.